Shares of these biotech companies are near their five-year highs after some strong performances in 2019.
News & Analysis: Axsome Therapeutics
Two pharma stocks, one riding a wave of enthusiasm and one getting unfairly punished, look appealing from a long-term standpoint.
The stock had an amazing run in 2019, with a 3,578% gain. What will happen in 2020?
An important drug candidate failed to meet its primary endpoint in a clinical trial. That left the door open for a new competitor.
Seven biotechs led the way.
Three very different areas of healthcare. One big common denominator: great growth prospects.
Find out what's behind the biopharmaceutical industry's top-performing stock of the year.
These stocks have soared 935% or more this year. Can they keep the momentum going?
Here's why these drugmaker stocks are the year's top performers.
Acadia Pharmaceuticals and Axsome Therapeutics are top buyout candidates heading into the new year.